Kane Biotech Announces Exercise of Warrants
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced the exercise of 5 million warrants at an exercise price of $0.10 per common share, resulting in total proceeds of $500,000. The company's President & CEO, Marc Edwards, stated that the shares are being held by long-term supporters of Kane. The proceeds from these warrant exercises will be utilized for general working capital purposes, providing the company with additional financial resources for its operations.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ha annunciato l'esercizio di 5 milioni di warrant a un prezzo di esercizio di $0,10 per azione ordinaria, con un totale di proventi pari a $500,000. Il presidente e CEO della società, Marc Edwards, ha dichiarato che le azioni sono detenute da sostenitori a lungo termine di Kane. I proventi derivanti da questi esercizi di warrant saranno utilizzati per scopi generali di capitale circolante, fornendo così alla società ulteriori risorse finanziarie per le sue operazioni.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ha anunciado el ejercicio de 5 millones de warrants a un precio de ejercicio de $0,10 por acción común, resultando en unos ingresos totales de $500,000. El presidente y CEO de la compañía, Marc Edwards, declaró que las acciones están siendo mantenidas por seguidores a largo plazo de Kane. Los ingresos de estos ejercicios de warrants se utilizarán para fines generales de capital de trabajo, proporcionando a la empresa recursos financieros adicionales para sus operaciones.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF)는 500만 개의 워런트 행사를 발표했습니다며, 행사 가격은 $0.10 per 보통 주식이고, 총 수익은 $500,000에 달합니다. 회사의 사장이자 CEO인 Marc Edwards는 이 주식이 Kane의 장기 지지자들에 의해 보유되고 있다고 밝혔습니다. 이 워런트 행사에서 발생한 수익은 일반 운영 자본 목적에 사용될 것이며, 회사의 운영을 위한 추가 재정을 제공합니다.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) a annoncé l'exercice de 5 millions de bons de souscription à un prix d'exercice de $0,10 par action ordinaire, aboutissant à des revenus totaux de $500,000. Le président et PDG de l'entreprise, Marc Edwards, a déclaré que les actions sont détenues par des soutiens à long terme de Kane. Les recettes tirées de ces exercices de bons de souscription seront utilisées pour des besoins généraux de fonds de roulement, offrant à l'entreprise des ressources financières supplémentaires pour ses opérations.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) hat die Ausübung von 5 Millionen Warrants zu einem Ausübungspreis von $0,10 pro Stammaktie angekündigt, was zu Gesamterlösen von $500.000 führt. Der Präsident und CEO des Unternehmens, Marc Edwards, erklärte, dass die Aktien von langfristigen Unterstützern von Kane gehalten werden. Die Erlöse aus diesen Warrants werden für allgemeine Betriebskapitalzwecke verwendet, wodurch das Unternehmen zusätzliche finanzielle Mittel für seine Operationen erhält.
- Raised $500,000 through warrant exercises
- Increased working capital for general purposes
- Demonstrated support from long-term investors
- None.
WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the exercise of an aggregate of 5 million warrants at an exercise price of
“The shares are being held by some long-term supporters of Kane,” said Marc Edwards, President & CEO.
The proceeds from these warrant exercises will be used for general working capital purposes.
About Kane Biotech
Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (68 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information:
| Marc Edwards | Ray Dupuis | ||||
| Chief Executive Officer | Chief Financial Officer | ||||
| Kane Biotech Inc | Kane Biotech Inc | ||||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | ||||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
How many warrants were exercised in Kane Biotech's recent announcement?
What was the exercise price for Kane Biotech's warrants?
How much capital did Kane Biotech raise from the warrant exercise?
What will Kane Biotech use the proceeds from the warrant exercise for?
